Jupiter Neurosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JUNS | NRSN | 18H0.F | QNTM | ENVB | BIVI | |
|---|---|---|---|---|---|---|
| Market cap | 3.24M | 2.69M | 5.11M | 14.21M | 6.53M | 11.63M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 41.0 | -0.3 | — | -0.3 | -1.0 | -2.4 |
| Price/book | -4.5 | -1.5 | -1.1 | 2.1 | 0.7 | 1.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −97.59% | −93.11% | −25.00% | −74.27% | −75.83% | −10.67% |
| Today | +1.23% | +9.23% | −23.81% | 0.00% | −2.67% | −22.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All JUNS news ›PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
“This Agreement is a landmark transaction for PharmAla and its shareholders. It delivers near-term capital, meaningful milestone and royalty participation, and a dedicated U.S. development partner in ...
Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal
The deal includes a $3.3 million upfront payment, split between cash and Jupiter Neurosciences stock. Additional milestones include $3.3 million when the Phase 3 trial begins, $20 million upon U.S. Food and Drug Administration (FDA)…
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its P... Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights…
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth In academia, Dr. Philipson holds the Daniel Levin Chair of Public Policy Emeritus at…
Jupiter Neurosciences doses first patient in Parkinson’s disease Phase 2a trial
Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial of JOTROL in Parkinson’s disease, marking a clinical milestone. RESET is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll…
More from 3 other outlets
- clinicaltrialvanguard.com Jupiter Neurosciences Doses First Parkinson’s Patient in JOTROL Phase 2a Trial
- Quiver Quantitative Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial of JOTROL for Parkinson’s Disease and Reviews Strategic Alternatives
- TradingView Jupiter Neurosciences Announces First Patient Dosed In Phase 2A Reset Trial In Parkinson’S Disease
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Netlist and Micron Enter Patent License and Settlement Agreements Jupiter has also engaged Tungsten Advisors to explore strategic options. Potential paths include asset sales or licensing, partnerships, business combinations and other…
PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences
PharmAla (MDXXF) announced that it has entered into a definitive license agreement on July 20 with Jupiter Neurosciences (JUNS), under which Pha... PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences PharmAla…
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a license agreement, enrollment completion and a patent filing. Guggenheim lowered the firm’s price target on Helus Pharma to…
Jupiter Neurosciences Inc trading halted, news pending
19:50 EDT Jupiter Neurosciences (JUNS) Inc trading halted, news pendingClaim 55% Off TipRanks Unlock powerful investing tools with TipRanks Prem... Jupiter Neurosciences Inc trading halted, news pending 19:50 EDT Jupiter Neurosciences…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- markets.financialcontent.com2
- quiverquant.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.